Design Therapeutics (DSGN) Other Accumulated Expenses (2020 - 2021)

Design Therapeutics (DSGN) reported Other Accumulated Expenses of $239000.0 for Q2 2021, up 25.13% sequentially from $191000.0 in Q1 2021.

Design Therapeutics (DSGN) Other Accumulated Expenses (2020 - 2021) Analysis & Trends

Design Therapeutics (DSGN) has 2 years of Other Accumulated Expenses data on file, last reported at $239000.0 in Q2 2021.

For the quarter ending Q2 2021, Other Accumulated Expenses changed N/A year-over-year to $239000.0; the trailing twelve-month figure through Jun 2021 stood at $239000.0 (changed N/A YoY), and the FY2020 full-year result was $100000.0, changed N/A from the prior year.
Other Accumulated Expenses rose to $239000.0 in Q2 2021, from $191000.0 in the prior quarter.
In the past five years, Other Accumulated Expenses ranged from a high of $239000.0 in Q2 2021 to a low of $100000.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,140.12 Bn	66,139.83 Bn	-
2	Nanobiotix	1,933.82 Bn	1,933.76 Bn	-
3	Akari Therapeutics	1,022.34 Bn	1,022.34 Bn	-
4	BeOne Medicines	472.04 Bn	467.25 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.28 Bn	115.03 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.07 Bn	61.31 Bn	3.31 Bn
7	Belite Bio	62.66 Bn	62.66 Bn	-
8	Argenx Se	56.16 Bn	50.98 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.56 Bn	34.55 Bn	959.66 Mn
10	Design Therapeutics	739.30 Mn	516.47 Mn	-

Download Data